临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1542705-92-9

CB-5083

CAS号:1542705-92-9
分子式: C24H23N5O2 分子量: 413.47
产品形式: free base
研发状态: Terminated
研发用途: Advanced Solid Tumors
研究机构: Cleave Biosciences Inc.
研发日期: October 11 2014
研发阶段: Phase 1
CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor with IC50 of 11 nM. Phase 1.

CAS: 154235-83-3

Ampalex (CX-516)

中文名称:安帕来斯
CAS号:154235-83-3
分子式: C14H15N3O 分子量: 241.29
产品形式: Free Base
研发状态: Completed
研发用途: Schizophrenia
研究机构: North Suffolk Mental Health Association; RespireRx
研发日期: Feb-02
研发阶段: Phase 2 : Phase 3
Ampalex (CX-516, Ampakine CX 516, BDP-12, SPD 420) is a positive allosteric modulator of AMPA receptor. Ampalex exhibits potential treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).

CAS: 154-17-6

2-Deoxy-D-glucose (2-DG)

中文名称:2-脱氧-D-葡萄糖
CAS号:154-17-6
分子式: C6H12O5 分子量: 164.16
产品形式: free base
研发状态: Completed
研发用途: Neoplasms
研究机构: Hoffmann-La Roche
研发日期: October 11 2015
研发阶段: Phase 1
2-Deoxy-D-glucose (2-DG, 2-deoxyglucose, NSC 15193, 2-Deoxy-D-arabino-hexose, D-Arabino-2-deoxyhexose), an analog of glucose, is a glycolytic inhibitor with antiviral activity. 2-Deoxy-D-glucose induces apoptosis and inhibits Herpes Simplex Virus type-1 (HSV-1) receptor expression.

CAS: 1539314-06-1

GSK-2881078

CAS号:1539314-06-1
分子式: C14H13F3N2O2S 分子量: 330.33
产品形式: Free Base
研发状态: Completed
研发用途: Cachexia
研究机构: GlaxoSmithKline; Parexel
研发日期: February 28 2018
研发阶段: Phase 2
GSK 2881078 is a nonsteroidal selective modulator of androgen receptor that is potentially used for the treatment of cachexia.

CAS: 153559-49-0

Bexarotene (LGD1069)

中文名称:蓓萨罗丁
CAS号:153559-49-0
分子式: C24H28O2 分子量: 348.00
产品形式: free base
研发状态: Completed
研发用途: Breast Atypical Ductal Hyperplasia; Breast Atypical Lobular Hyperplasia; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ; Invasive Breast Carcinoma
研究机构: National Cancer Institute (NCI)
研发日期: June 15 2018
研发阶段: Phase 1
Bexarotene (Targretin, LGD1069) is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.

CAS: 153504-70-2

Cevimeline HCl hemihydrate

中文名称:盐酸西维美林
CAS号:153504-70-2
分子式: C10H18ClNOS.1/2H2O 分子量: 244.78
产品形式: HCl hemihydrate
研发状态: Completed
研发用途: Xerostomia
研究机构: American Academy of Otolaryngology-Head and Neck Surgery Foundation; Duke University
研发日期: May-07
研发阶段: Phase 4
Cevimeline HCl hemihydrate(AF 102B, SNI 2011, SNK 508) is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.